Targeting the tumor vasculature to enhance T cell activity

Current Opinion in Immunology

Volumn 33, Issue , 2015, Pages 55-63

  Lanitis, Evripidis ^a   Irving, Melita ^a   Coukos, George ^a,b,c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CAPECITABINE; CETUXIMAB; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; DNA VACCINE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ALPHACD137; OXALIPLATIN; SUNITINIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2;

ACTIVE IMMUNIZATION; ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CELL ACTIVITY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; EFFECTOR CELL; ENDOTHELIUM; HUMAN; KIDNEY CARCINOMA; METASTATIC COLORECTAL CANCER; METRONOMIC DRUG ADMINISTRATION; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR IMMUNOLOGY; TUMOR VASCULARIZATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROCEDURES; T LYMPHOCYTE;

ANIMALS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; T-LYMPHOCYTES;

EID: 84922369778     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.01.011     Document Type: Review

References (147)

1. Coulie P.G., et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014, 14:135-146.
2. Barry M., Bleackley R.C. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2002, 2:401-409.
3. Kennedy R., Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 2008, 222:129-144.
4. Zhang L., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.
5. Galon J., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
6. Gao Q., et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007, 25:2586-2593.
7. Gooden M.J., et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011, 105:93-103.
8. Czerniecki B.J., et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007, 67:1842-1852.
9. Kandalaft L.E., et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013, 2:pe22664.
10. Rosenberg S.A., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17:4550-4557.
11. Chapuis A.G., et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med 2013, 5:174ra27.
12. Robbins P.F., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011, 29:917-924.
13. Porter D.L., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733.
14. Maude S.L., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014, 371:1507-1517.
15. Grupp S.A., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368:1509-1518.
16. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012, 12:269-281.
17. Barrett D.M., et al. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014, 65:333-347.
18. Hinrichs C.S., et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 2011, 117:808-814.
19. Irving M., et al. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem 2012, 287:23068-23078.
20. Aleksic M., et al. Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time. Immunity 2010, 32:163-174.
21. Zhong S., et al. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc Natl Acad Sci U S A 2013, 110:6973-6978.
22. Motz G.T., Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013, 39:61-73.
23. Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013, 39:1-10.
24. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
25. Gajewski T.F., et al. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 2011, 23:286-292.
26. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
27. Spranger S., et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013, 5:200ra116.
28. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007, 25:267-296.
29. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
30. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
31. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
32. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20:4368-4380.
33. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011, 17:1359-1370.
34. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
35. Palazon A., et al. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res 2012, 18:1207-1213.
36. De Bock K., Cauwenberghs S., Carmeliet P. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 2011, 21:73-79.
37. Dayan F., et al. A dialogue between the hypoxia-inducible factor and the tumor microenvironment. Cancer Microenviron 2008, 1:53-68.
38. Ley K., Kansas G.S. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. Nat Rev Immunol 2004, 4:325-335.
39. Weber C., Fraemohs L., Dejana E. The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol 2007, 7:467-477.
40. Ala A., Dhillon A.P., Hodgson H.J. Role of cell adhesion molecules in leukocyte recruitment in the liver and gut. Int J Exp Pathol 2003, 84:1-16.
41. Shetty S., et al. Common lymphatic endothelial and vascular endothelial receptor-1 mediates the transmigration of regulatory T cells across human hepatic sinusoidal endothelium. J Immunol 2011, 186:4147-4155.
42. Mazanet M.M., Hughes C.C. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 2002, 169:3581-3588.
43. Rodig N., et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol 2003, 33:3117-3126.
44. Huang D., et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010, 70:1063-1071.
45. Zang X., et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 2010, 23:1104-1112.
46. Kraan J., et al. Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells. Br J Cancer 2014, 111:149-156.
47. Krambeck A.E., et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A 2006, 103:10391-10396.
48. Riesenberg R., et al. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res 2007, 13:6993-7002.
49. Blaschitz A., et al. Vascular endothelial expression of indoleamine 2,3-dioxygenase 1 forms a positive gradient towards the feto-maternal interface. PLoS ONE 2011, 6:e21774.
50. Frumento G., et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002, 196:459-468.
51. Mulligan J.K., Young M.R. Tumors induce the formation of suppressor endothelial cells in vivo. Cancer Immunol Immunother 2010, 59:267-277.
52. Pirtskhalaishvili G., Nelson J.B. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000, 44:77-87.
53. Casos K., et al. Tumor cells induce COX-2 and mPGES-1 expression in microvascular endothelial cells mainly by means of IL-1 receptor activation. Microvasc Res 2011, 81:261-268.
54. Taflin C., et al. Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proc Natl Acad Sci U S A 2011, 108:2891-2896.
55. Sata M., Walsh K. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998, 4:415-420.
56. Yu J.S., et al. Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium. J Neurooncol 2003, 64:55-61.
57. Motz G.T., et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014, 20:607-615.
58. Secchiero P., Zauli G. The puzzling role of TRAIL in endothelial cell biology. Arterioscler Thromb Vasc Biol 2008, 28. e4, author reply e5-e6.
59. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8:579-591.
60. Dikov M.M., et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 2005, 174:215-222.
61. Gabrilovich D.I., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2:1096-1103.
62. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012, 12:253-268.
63. Ferrara N., et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3:391-400.
64. Koukourakis G.V. Has bevacizumab (Avastin) given extra therapeutic gain in metastatic colorectal cancer and malignant brain gliomas? Systematic review answering this question. Recent Pat Inflamm Allergy Drug Discov 2012, 6:70-77.
65. Shih T., Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006, 28:1779-1802.
66. Miller D.W., et al. Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants. Am J Pathol 2005, 167:1389-1403.
67. Winkler F., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
68. Tong R.T., et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64:3731-3736.
69. Dirkx A.E., et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 2006, 20:621-630.
70. Manzoni M., et al. Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology 2010, 79:187-196.
71. Terme M., et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013, 73:539-549.
72. Osada T., et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008, 57:1115-1124.
73. Gotink K.J., Verheul H.M. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?. Angiogenesis 2010, 13:1-14.
74. Adotevi O., et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010, 33:991-998.
75. Ko J.S., et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009, 15:2148-2157.
76. Finke J.H., et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008, 14:6674-6682.
77. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
78. ten Hagen T.L., Seynhaeve A.L., Eggermont A.M. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. Immunol Rev 2008, 222:299-315.
79. Bouzin C., Feron O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist Updat 2007, 10:109-120.
80. Griffioen A.W., et al. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 1996, 56:1111-1117.
81. Nelson J., et al. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003, 3:110-116.
82. Salani D., et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000, 157:1703-1711.
83. Spinella F., et al. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem 2002, 277:27850-27855.
84. Rosano L., Spinella F., Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2013, 13:637-651.
85. Buckanovich R.J., et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008, 14:28-36.
86. Rajeshkumar N.V., Rai A., Gulati A. Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats. Breast Cancer Res Treat 2005, 94:237-247.
87. Cemazar M., et al. The endothelin B (ETB) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification. Br J Cancer 2005, 93:98-106.
88. Palladino M.A., et al. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol 1987, 138:4023-4032.
89. Lenk H., et al. Phase II clinical trial of high-dose recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1989, 24:391-392.
90. Abbruzzese J.L., et al. A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity. J Biol Response Mod 1990, 9:522-527.
91. Curnis F., et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000, 18:1185-1190.
92. Curnis F., Sacchi A., Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002, 110:475-482.
93. Sacchi A., et al. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin Cancer Res 2006, 12:175-182.
94. Calcinotto A., et al. Targeting TNF-alpha to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol 2012, 188:2687-2694.
95. Johansson A., et al. Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A 2012, 109:7841-7846.
96. Melero I., et al. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998, 190:167-172.
97. Choi B.K., et al. 4-1BB functions as a survival factor in dendritic cells. J Immunol 2009, 182:4107-4115.
98. Broll K., et al. CD137 expression in tumor vessel walls, high correlation with malignant tumors. Am J Clin Pathol 2001, 115:543-549.
99. Palazon A., et al. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res 2011, 71:801-811.
100. Melero I., et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997, 3:682-685.
101. Wilcox R.A., et al. Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood 2004, 103:177-184.
102. Ito F., et al. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res 2004, 64:8411-8419.
103. Rafii S. Vaccination against tumor neovascularization: promise and reality. Cancer Cell 2002, 2:429-431.
104. Li Y., Bohlen P., Hicklin D.J. Vaccination against angiogenesis-associated antigens: a novel cancer immunotherapy strategy. Curr Mol Med 2003, 3:773-779.
105. Li Y., et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 2002, 195:1575-1584.
106. Niethammer A.G., et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002, 8:1369-1375.
107. Luo Y., et al. FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice. Vaccine 2007, 25:1409-1415.
108. Wang Y.S., et al. Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFlk-1. Clin Cancer Res 2007, 13:6779-6787.
109. Xie K., et al. Anti-tumor effects of a human VEGFR-2-based DNA vaccine in mouse models. Genet Vaccines Ther 2009, 7:p10.
110. Zuo S.G., et al. Orally administered DNA vaccine delivery by attenuated Salmonella typhimurium targeting fetal liver kinase 1 inhibits murine Lewis lung carcinoma growth and metastasis. Biol Pharm Bull 2010, 33:174-182.
111. Wei Y.Q., et al. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci U S A 2001, 98:11545-11550.
112. Okaji Y., et al. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci 2004, 95:85-90.
113. Wei Y.Q., et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000, 6:1160-1166.
114. Christian S., et al. Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J Biol Chem 2001, 276:7408-7414.
115. Bagley R.G., et al. Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248. Mol Cancer Ther 2008, 7:2536-2546.
116. Rettig W.J., et al. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci U S A 1992, 89:10832-10836.
117. Walter-Yohrling J., et al. Murine endothelial cell lines as models of tumor endothelial cells. Clin Cancer Res 2004, 10:2179-2189.
118. Buckanovich R.J., et al. Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 2007, 25:852-861.
119. Simonavicius N., et al. Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. Mod Pathol 2008, 21:308-315.
120. MacFadyen J.R., et al. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett 2005, 579:2569-2575.
121. Facciponte J.G., et al. Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. J Clin Invest 2014, 124:1497-1511.
122. Santoro S.K., Motz S., Alatzoglou G.T., Li D., Chungsheng, Irving M., Powell D.J., Coukos G. T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. Cancer Immunol Res 2015, 3:68-84.
123. Sadelain M., Brentjens R., Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013, 3:388-398.
124. Chinnasamy D., et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest 2010, 120:3953-3968.
125. Wang W., et al. Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. Gene Ther 2013, 20:970-978.
126. Chinnasamy D., et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 2012, 18:1672-1683.
127. Chinnasamy D., et al. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Cancer Res 2013, 73:3371-3380.
128. Lanitis E., et al. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res 2013, 1:43-53.
129. Kloss C.C., et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013, 31:71-75.
130. Fedorov V.D., Themeli M., Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 2013, 5:215ra172.
131. Straathof K.C., et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005, 105:4247-4254.
132. Di Stasi A., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011, 365:1673-1683.
133. Vogler I., et al. An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol Ther 2010, 18:1330-1338.
134. Morgan R.A., et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010, 18:843-851.
135. Yang J.C., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
136. Cobleigh M.A., et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003, 30(Suppl. 16):117-124.
137. Mayer R.J. Two steps forward in the treatment of colorectal cancer. N Engl J Med 2004, 350:2406-2408.
138. Hollebecque A., Massard C., Soria J.C. Vascular disrupting agents: a delicate balance between efficacy and side effects. Curr Opin Oncol 2012, 24:305-315.
139. Hurwitz H., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
140. Bellone M., Mondino A., Corti A. Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. Trends Immunol 2008, 29:235-241.
141. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002, 6:1-12.
142. Hanahan D., Bergers G., Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000, 105:1045-1047.
143. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4:423-436.
144. Cham K.K., et al. Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer 2010, 103:52-60.
145. Chiang C.L., et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 2013, 19:4801-4815.
146. Voron T., et al. Control of the immune response by pro-angiogenic factors. Front Oncol 2014, 4:70.
147. Tol J., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360:563-572.